Clinical Trial: Optimal Timing of Microaxial Flow Pump(Impella CP) in AMI-related Cardiogenic Shock

U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07817472) titled 'Optimal Timing of Microaxial Flow Pump(Impella CP) in AMI-related Cardiogenic Shock' on Sept. 06.

Brief Summary: PRIME-SHOCK is a prospective, single-center, open-label, randomized, superiority trial. Eligible participants with AMICS and a clinical decision to use Impella CP will be randomized in a 1:1 ratio before culprit-lesion PCI. The routine pre-PCI group will undergo Impella CP insertion immediately after allocation and before culprit-lesion PCI. The selective post-PCI group will undergo culprit-lesion PCI first; Impella CP will be inserted only if prespecified intra-procedural rescue criteria are met or shock persists or wor...